at://
/
app.bsky.feed.post
/
3mnstc5g3t22n
sign in
All
4
Record
2
Post
1
PostEmbed
1
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Noxopharm (ASX:NOX) starts manufacturing SOF-SKN™ to support planned clinical trial targeting cutaneous lupus erythematosus, with low supply chain risks and strong stability. bit.ly/4vBN1Xw
4d
bit.ly
